Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in PediatricsReferences
- Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication (NCS-A).J Am Acad Child Adolesc Psychiatry. 2010; 49: 980-989
- Clinical effectiveness of new generation antipsychotics in adolescent patients.Eur Neuropsychopharmacol. 2004; 14: 471-479
- Enhancing pediatric mental health care: report from the American Academy of Pediatrics Task Force on Mental Health. Introduction.Pediatrics. 2010; 125: S69-S74
- The future of pediatrics: mental health competencies for pediatric primary care.Pediatrics. 2009; 124: 410-421
- Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings.Pediatrics. 2000; 107: e43
- The great smoky mountains study of youth. goals, design, methods, and the prevalence of DSM-III-R disorders.Arch Gen Psychiatry. 1996; 53: 1129-1136
- Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, United States, 2006.Mobid Mortal Week Rep. 2009; 58: 1-20
- Autistic spectrum disorders: changes in the California caseload, an update June 1987-June 2007: California Health and Human Services Agency. State of California 2003 survey of developmental disabilities.(Available at:) (Accessed December 5, 2011)
- Off-label prescribing among office-based physicians.Arch Intern Med. 2006; 166 ([psychiatric drugs]): 1021-1026
- Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.Child Adolesc Psychiatry Ment Health. 2008; 2: 24
- New users of antipsychotic medication among children enrolled in TennCare.Arch Pediatr Adolesc Med. 2004; 158: 753-759
- Use of antipsychotics in children.Psychiatry (Edgmont). 2009; 6: 21-23
- Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000.J Child Adolesc Psychopharmacol. 2002; 12: 221-229
- Trends in prescribing of antipsychotic medications for US children.Ambul Pediatr. 2006; 6: 79-83
- (Available at:) (Accessed December 5, 2011)
- Cognitive-behavioral therapy, sertraline and their combination for children and adolescents with anxiety disorders: acute phase efficacy and safety.N Engl J Med. 2008; 359: 2753-2766
- Pediatric obsessive-compulsive disorder treatment Study.J Am Acad Child Adolesc Psychiatry. 2004; 292: 1969-1976
- Enhancing pediatric mental health care: strategies for preparing a community.Pediatrics. 2010; 125: S75-S86
- Youth risk behavior surveillance—United States, 2005.MMWR Surveill Summ. 2006; 55: 1-108
- Treatment for adolescents with Depression Study (TADS): long-term effectiveness and safety.Arch Gen Psychiatry. 2007; 64: 1132-1143
- The MTA Cooperative Group: a 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder.Arch Gen Psychiatry. 1999; 56: 1073-1086
- Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.Pediatrics. 2001; 108: 1033-1044
- Practice parameters for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.J Am Acad Child Adolesc Psychiatry. 2007; 46: 894-921
- Medication use among children with autism spectrum disorders.J Child Adolesc Psychopharmacol. 2007; l17: 348-355
- (Available at:) (Study Accessed December 5, 2011)
- Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on drug metabolism.Clinical Pharmacokinet. 1997; 32: 1-21
- Pharmacokinetics of the selective serotonin reuptake inhibitors.J Clin Psychiatry. 1992; 53: 13-20
- The Food and Drug Administration’s deliberations on antidepressants use in pediatric patients.Pediatrics. 2005; 116: 195-201
- Suicide rates in clinical trials of SSRIs other antidepressants and placebo: analysis of FDA reports.Am J Psychiatry. 2003; 160: 790-792
- Suicidality in pediatric patients treated with antidepressant drugs.Arch Gen Psychiatry. 2006; 63: 332-339
- Antidepressants and the risk of suicidal behaviors.JAMA. 2004; 292: 338-343
- American College of Neuropsychopharmacology, preliminary report of the task force on SSRI’s and suicidal behavior in youth.(Available at:)www.ancp.org(Accessed December 5, 2011)Date: 2004
U.S. FDA Public Health Advisory: suicidality in children and adolescents being treated with antidepressant medications; 2004.
- Relationship between antidepressant medication treatment and suicide in adolescents.Arch Gen Psychiatry. 2003; 60: 978-982
- Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents.Am J Psychiatry. 2007; 164: 1356-1363
- Health advisories: when good intentions go bad.CMAJ. 2008; 178: 1025-1026
- Effects of regulatory warnings on antidepressant prescribing rates, use of health services and outcomes among children, adolescents and young adults.CMAJ. 2008; 178: 1005-1011
- Practice parameter for the assessment and treatment of children and adolescents with depressive disorders.J Am Acad Child Adolesc Psychiatry. 2007; 46: 1503-1536
- The serotonin syndrome.N Engl J Med. 2005; 352: 1112-1120
- Serotonin syndrome: a brief review.CMAJ. 2003; 168: 1439-1442
- Serotonin reuptake inhibitor withdrawal.J Clin Psychopharmacol. 1996; 16: 356-362
- Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.JAMA. 2005; 293: 2372-2383
- Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.Arch Gen Psychiatry. 2003; 60: 720-726
- Neonatal withdrawal syndrome after in utero exposure to serotonin reuptake inhibitors.Acta Paediatr. 2001; 90: 288-291
- Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.N Engl J Med. 2006; 354: 579-587
- Selective serotonin reuptake inhibitors (SSRI) for autism spectrum disorders (ASD).Cochrane Database Syst Rev. 2010; 8 (CD004677)
- (STAART Psychopharmacology Network): lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.Arch Gen Psychiatry. 2009; 66: 583-590
- The behavior of children receiving benzedrine.Am J Psychiatry. 1937; 94: 577-585
- Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?.J Am Acad Child Adolesc Psychiatry. 1996; 35: 1460-1469
- Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.J Am Acad Child Adolesc Psychiatry. 2007; 46: 1015-1027
- Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses.J Am Acad Child Adolesc Psychiatry. 2007; 46: 1002-1013
- A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.J Pediatr. 2010; 157 (e1): 635-640
- Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD.Neuropediatrics. 2010; 41: 55-59
- Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.J Am Acad Child Adolesc Psychiatry. 2009; 48: 884-893
- Effects of methylphenidate discontinuation and reinitiation in children with Tourette’s syndrome and ADHD.J Child Adolesc Psychopharmacol. 1995; 5: 205
- Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?.J Am Acad Child Adolesc Psychiatry. 1999; 38: 944-951
- Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder.Arch Gen Psychiatry. 1995; 52: 444-455
- Long term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder.Arch Gen Psychiatry. 1999; 56: 330-336
- Drug and non-drug treatments of children with ADHD and tic disorders.Eur Child Adolesc Psychiatry. 2007; 16: 78-88
- Treatment of ADHD in children with tics: a randomized controlled trial.Neurology. 2002; 58: 527-536
- A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.Pediatrics. 2002; 109: e39
- Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention-deficit/hyperactivity disorder: 2-year, open-label study results.Pediatrics. 2007; 120: e120-e128
- U.S. Food and Drug Administration (2005) public health advisory for Adderall and Adderall XR.(Available at:) (Accessed January 24, 2006)
- US regulators puzzled by Canada’s ruling on safety of ADHD drug.Psychiatr News. 2005; 40: 5-9
Adderall XR [package insert]. Wayne, PA: Shire US Inc; 2010.
Concerta [package insert]. Titusville, NJ: McNeil Pediatrics; 2008.
Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
- A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.Circulation. 2008; 117: 2407-2423
- Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.Can J Cardiol. 2009; 25: 625-630
- Does prior exposure to stimulants in children with ADHD impact cardiovascular parameters from lisdexamfetamine dimesylate?.Postgrad Med. 2010; 122: 27-34
- Cardiovascular monitoring and stimulant drugs for attention deficit hyperactivity disorder.Pediatrics. 2008; 122: 451-453
- Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? a meta-analytic review of the literature.Pediatrics. 2003; 111: 179-185
- Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood.Am J Psychiatry. 2008; 165: 604-609
- Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study.Am J Psychiatry. 2008; 165: 597-603
- Effects of ADHD, conduct disorder, and gender on substance use and abuse in adolescence.Am J Psychiatry. 1999; 156: 1515-1521
- Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects.J Am Acad Child Adolesc Psychiatry. 2007; 46: 1028-1040
- Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.J Child Adolesc Psychopharmacol. 2007; 17: 153-164
- ADHD in preschoolers: a diagnosis—or just a “PhAse”?.Consultant for Pediatricians. 2008; 8: S2-S8
- Comparing the efficacy of medications for ADHD using meta-analysis.Medscape General Medicine. 2006; 8: 4
- Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.J Am Acad Child Adolesc Psychiatry. 2009; 48: 176-185
- Clinical utility of EEG in attention deficit hyperactivity disorder.Appl Neuropsychol. 2005; 12: 64-76
- Neurofeedback training in children with ADHD: 6-month follow-up of a randomized controlled trial.Eur Child Adolesc Psychiatry. 2010; 19: 715-724
- Is neurofeedback an efficacious treatment for ADHD? A randomized controlled clinical trial.J Child Psychol Psychiatry. 2009; 50: 780-789
- Trends in the use of typical and atypical antipsychotics in children and adolescents.J Am Acad Child Adolesc Psychiatry. 2005; 44: 548-556
- National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.Arch Gen Psychiatry. 2006; 63: 679-685
- Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.Eur Neuropsychopharmacol. 2009; 19: 629-635
- A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.J Child Adolesc Psychopharmacol. 2009; 19: 575-582
- Akathesia and second generation antipsychotic drugs.Curr Opin Psychiatry. 2009; 22: 293-299
- Prevalence and severity of akathisia in patients on clozapine.Biol Psychiatry. 1991; 29: 1215-1219
- Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.Harv Rev Psychiatry. 2006; 14: 152-164
- Paediatric psychopharmacology: closing the gap between science and practice.Expert Opin Pharmacother. 2001; 2: 523-525
- Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents.J Child Adolesc Psychopharmacol. 2007; 17: 487-502
- Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.J Am Acad Child Adolesc Psychiatry. 2006; 45: 771-791
- Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.J Clin Psychiatry. 2008; 69: 26-30
- Cardiometabolic risk of second generation antipsychotic medications during first time use in child and adolescents.JAMA. 2009; 302: 1765-1773
- Efficacy and tolerabilityof second-generation antipsychotics in children and adolescent with schizophrenia.Schizophr Bull. 2008; 34: 60-71
- Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison.Arch Gen Psychiatry. 2006; 63: 721-730
- (Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators): effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med. 2005; 353: 1209-1223
- Double blind comparison of first- and second-generation antipsychotics in early onset schizophrenia: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.Am J Psychiatry. 2008; 165: 1420-1431
- Risperidone in children with autism and serious behavior problems.N Engl J Med. 2002; 347: 314-321
- Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.Am J Psychiatry. 2009; 166: 345
- Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.J Am Acad Child Adolesc Psychiatry. 2008; 47: 9-20
- Enhancing pediatric mental health care: strategies for preparing a primary care practice.Pediatrics. 2010; 125: S87-S108
Article info
Footnotes
Disclosures: Dr Robin Steinberg-Epstein is a consultant for McNeil; has received grant/research support from Addrenex, Eli Lilly & Co., McNeil, Next Wave Pharmaceuticals, Otsuka, Psychogenics, Quintiles, Shionogi Pharm., Shire, and the NIMH; is on the speaker or advisory boards for McNeil. Ms. Book has nothing to disclose. Dr Sharon B. Wigal is a consultant for Abbott, McNeil, NuTec, Shire, Taisho, and the NIMH; has received grant/research support from Addrenex, Eli Lilly & Co., McNeil, Next Wave Pharmaceuticals, Otsuka, Psychogenics, Quintiles, Shionogi Pharm., Shire, NICHD, and the NIMH; is on the speaker or advisory boards for Eli Lilly & Co., McNeil, Shionogi Pharm., and Shire.